Search
LIC-477
go.drugbank.com/drugs/DB05363ExperimentalLIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
Aprobarbital
go.drugbank.com/drugs/DB01352ExperimentalIllicitAprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects.
LAX-101
go.drugbank.com/drugs/DB05301InvestigationalLAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.
4-Phenylfentanyl
go.drugbank.com/drugs/DB09168ExperimentalIllicit4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted
Metformin C-11
go.drugbank.com/drugs/DB15181ExperimentalMetformin c-11 is under investigation in clinical trial NCT03122769 (Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography).
Panobacumab
go.drugbank.com/drugs/DB15342InvestigationalPanobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).
Bentiromide
go.drugbank.com/drugs/DB00522ApprovedWithdrawnBentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy. It is typically administered orally. C...
Teclozan
go.drugbank.com/drugs/DB13205InvestigationalTeclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.
CT103A
go.drugbank.com/drugs/DB18180InvestigationalCT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Salanersen
go.drugbank.com/drugs/DB18418InvestigationalBIIB115 is an investigational antisense oligonucleotide in development for spinal muscular atrophy.